According to Neurocrine Biosciences
's latest financial reports the company has A$1.71 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2024-12-31 | A$1.73 B | 14.26% |
2023-12-31 | A$1.51 B | 4.15% |
2022-12-31 | A$1.45 B | 48.17% |
2021-12-31 | A$0.98 B | -5.82% |
2020-12-31 | A$1.04 B | 8.78% |
2019-12-31 | A$0.95 B | 3.65% |
2018-12-31 | A$0.92 B | 39.81% |
2017-12-31 | A$0.66 B | 54.99% |
2016-12-31 | A$0.42 B | -18.08% |
2015-12-31 | A$0.52 B | 119.8% |
2014-12-31 | A$0.23 B | 44.94% |
2013-12-31 | A$0.16 B | -1.86% |
2012-12-31 | A$0.16 B | 32.23% |
2011-12-31 | A$0.12 B | 0.81% |
2010-12-31 | A$0.12 B | 109.85% |
2009-12-31 | A$59.51 M | -47.82% |
2008-12-31 | A$0.11 B | -44.41% |
2007-12-31 | A$0.20 B | -11.42% |
2006-12-31 | A$0.23 B | -37.93% |
2005-12-31 | A$0.37 B | -4.09% |
2004-12-31 | A$0.38 B | -36.17% |
2003-12-31 | A$0.60 B | 40.37% |
2002-12-31 | A$0.43 B | -30.72% |
2001-12-31 | A$0.62 B | 112.88% |
2000-12-31 | A$0.29 B | 112.44% |
1999-12-31 | A$0.13 B | 625.53% |
1998-12-31 | A$19.1 M | -21.21% |
1997-12-31 | A$24.25 M | 70.49% |
1996-12-31 | A$14.22 M |